Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.64 |
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849447 | 0.84 | CA1 (0.68) | CA1CA2CA9CA12GLA | |
| SCHEMBL31018735 | 0.81 | CA1 (0.65) | CA1CA2CA9CA12GLA | |
| SCHEMBL13004520 | 0.81 | LMNA (0.68) | CA1CA2CA9CA12GLA | |
| SCHEMBL5143254 | 0.81 | GLA (0.76) | CA1CA2CA9CA12GLA | |
| SCHEMBL5145990 | 0.80 | CA1 (0.64) | CA1CA2CA9CA12GLA | |
| SCHEMBL11913948 | 0.80 | CA1 (0.64) | CA1CA2CA9CA12GLA | |
| SCHEMBL28927348 | 0.80 | LMNA (0.76) | CA1CA2CA9CA12GLA | |
| SCHEMBL31018745 | 0.80 | CA1 (0.60) | CA1CA2CA9CA12GLA | |
| SCHEMBL4272926 | 0.79 | CA2 (0.60) | CA1CA2CA9CA12GLA | |
| SCHEMBL16151836 | 0.79 | GLA (0.78) | CA1CA2CA9CA12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | claimed |
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054884-A1 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | CLPP, TYR, MRPL21 | CA1 4873/4885CA2 4268/4885CA9 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.